Uncontrolled activation of macrophages promotes various inflammatory diseases. The most devastating diseases linked to macrophage activation include atherosclerosis, a global health burden. To discover novel regulators of macrophage activation as therapeutic targets, we performed global proteomics on IFN?- triggered M1 and IL-4-induced M2 macrophages. We identified PARP9 and PARP14, ADP-ribosylation enzymes, as key candidates. The functions of these two PARPs have not yet well characterized and their roles in macrophage biology or vascular disease are unknown. Based on our own preliminary findings, this multidisciplinary research project will test the novel hypothesis that PARP9 promotes and PARP14 suppresses macrophage activation.
In Specific Aims 1 and 2, we will use mouse models to examine the role of PARP9 and PARP14 in macrophage activation and atherosclerosis. Our pilot studies have demonstrated many new findings on the interplay between PARP9 and PARP14 and their associations with pro-inflammatory STAT1 and anti-inflammatory STAT6.
Specific Aim 2 also will use mass spectrometry and systems biology to explore the mechanisms by which the interactions between PARP9 and PARP14 regulate macrophage activation via ribosylation of signaling molecules (e.g., STAT1). Our study will reveal novel mechanisms of macrophage activation and provide a proof of concept that PARP9 and PARP14 can be therapeutic targets for atherosclerosis and its complications. Furthermore, the study will offer new insight into the shared mechanisms for various other inflammatory diseases, leading to exciting future directions and clinical translation.

Public Health Relevance

Inflammation in coronary arteries triggers acute complications of atherosclerosis (e.g., heart attack), the No.1 killer in the United States. The mechanism for arterial inflammation, however, remains incompletely understood. The present study will perform mouse experiments to dissect the new mechanisms of inflammation via PARP9 and PARP14. The potential outcomes will offer new therapeutic targets for vascular diseases and contribute to preventive cardiovascular medicine.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL126901-01A1
Application #
9028588
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Chen, Jue
Project Start
2016-01-01
Project End
2019-12-31
Budget Start
2016-01-01
Budget End
2016-12-31
Support Year
1
Fiscal Year
2016
Total Cost
$619,242
Indirect Cost
$219,424
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Singh, Sasha A; Aikawa, Masanori (2017) Unbiased and targeted mass spectrometry for the HDL proteome. Curr Opin Lipidol 28:68-77
Goettsch, Claudia; Iwata, Hiroshi; Hutcheson, Joshua D et al. (2017) Serum Sortilin Associates With Aortic Calcification and Cardiovascular Risk in Men. Arterioscler Thromb Vasc Biol 37:1005-1011
Goettsch, Claudia; Hutcheson, Joshua D; Hagita, Sumihiko et al. (2016) A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification. Atherosclerosis 251:109-118
Nakano, Toshiaki; Fukuda, Daiju; Koga, Jun-Ichiro et al. (2016) Delta-Like Ligand 4-Notch Signaling in Macrophage Activation. Arterioscler Thromb Vasc Biol 36:2038-47
Iwata, Hiroshi; Goettsch, Claudia; Sharma, Amitabh et al. (2016) PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. Nat Commun 7:12849
Georgianos, Panagiotis I; Agarwal, Rajiv (2016) Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nat Rev Nephrol 12:636-47